Patients treated with pembrolizumab plus paclitaxel with or without bevacizumab had a statistically significant and clinically meaningful improvement in PFS, regardless of PD-L1 status. Topline ...
A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease progression or death in ovarian cancer patients without BRCA mutations, a ...
Metformin use in mCRC patients improved PFS during first-line 5-fluorouracil-based chemotherapy, but no OS benefit was observed. The study suggests metformin's potential as an adjunct therapy in mCRC, ...
Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...
Baseline and Longitudinal Neutrophil-to-Lymphocyte Ratio as Prognostic Factor for Metastatic Colorectal Cancer: A Secondary Analysis of the ITACa Randomized Trial Across the 42 analysis units and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results